Results 41 to 50 of about 743 (109)

Long‐term efficacy of adjunctive cenobamate: Open‐label extension of a randomized, placebo‐controlled study in a multinational Asian population

Epilepsia, EarlyView.
Long‐term efficacy and safety of adjunctive cenobamate in a multinational Asian population. Open‐label extension (OLE) efficacy population included all patients who had taken ≥1 dose of study drug and had any seizure data during the OLE maintenance phase.
Sang Kun Lee, Peimin Yu, Eunyeong Choe, Louis Ferrari, Kyoung Heo, Seung Bong Hong, Zhen Hong, Koji Iida, Yong Heui Jeon, Jiwon Jung, Marc Kamin, Kensuke Kawai, Ji Hyun Kim, Myung Won Kim, Xiaorong Liu, Jungshin Park, William Rosenfeld, Takamichi Yamamoto, Dong Zhou, Suiqiang Zhu, Sunita N. Misra   +20 more
wiley   +1 more source

Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein

, 2022
To explore the pathophysiological mechanisms of antiseizure and adverse behavioural/psychiatric effects of brivaracetam and levetiracetam, in the present study, we determined the effects of brivaracetam and levetiracetam on astroglial L-glutamate release
Kouji Fukuyama, Fukuyama, Kouji, Okada, Motohiro, Motohiro Okada   +3 more
core   +1 more source

Beyond seizure control: Non–seizure‐related outcomes in focal‐onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study

Epilepsia, EarlyView.
Abstract Objective Cenobamate is approved for treatment of focal seizures in adults, but evidence on non‐seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal‐onsEt SeizureS (BLESS) study evaluated patient‐ and clinician‐reported outcomes for up to 52 weeks of cenobamate treatment.
Simona Lattanzi, Giuseppe d'Orsi, Maria Teresa Di Claudio, Alfredo D'Aniello, Stefano Luca Sensi, Fedele Dono, Mariangela Panebianco, Luigi Sicurella, Alessandra Di Liberto, Andrea Novara, Carlo Di Bonaventura, Paolo Bonanni, Claudio Liguori, Federica Ranzato, Antonio Gambardella, Francesca Bisulli, Patrizia Pulitano, Giada Pauletto, Elena Tartara, Giampaolo Vatti, Giovanni Assenza, Alfonso Giordano, Anna Elisabetta Vaudano, Gionathan Mazza, Angela La Neve, Pietro Pignatta, Simone Beretta, Marianna Pezzella, Michela Cecconi, Chiara Pizzanelli, Vincenzo Andreone, Catello Vollono, Monica Puligheddu, Massimo Gangitano, Daniela Audenino, Nicoletta Foschi, Elisa Fallica, Giovanni Boero, David Stokelj, Maria Pia Pasolini, Luciana Tramacere, Gionata Strigaro, Edoardo Ferlazzo, Tiziano Zanoni, Pietro Penza, Maurizio Elia, Stefano Quadri, Giovanni De Maria, Monica Santo Sabato, Loretta Giuliano, Rosita Galli, Angelo Labate, Filippo Dainese, Giovanni Falcicchio, Roberto De Simone, Michela Procaccini, Valentina Villano, Gabriele Camattari, Daniele Andreis, Lucia Simoni, Giancarlo Di Gennaro, on behalf of the BLESS Study Group, Cecilia Catania, Alessandra Morano, Biagio Orlando, Maria Sole Borioni, Fabrizio Giaculli, Luca Pasquale Giordano, Francesca Pia Mazzeo, Marco Belluzzo, Anna Carmen Nilo, Alessia Peretti, Diana Polo, Anna Bolzan, Giulia Lippa, Marianna Nesta, Lorenzo Ricci, Felice Altieri, Alberto Danieli, Elisa Osanni, Francesco Fortunato, Giuseppe Magro, Laura Marino, Ilaria Sammarra, Francesca Felicia Operto, Carlo Andrea Galimberti, Domenico Lomonaco, Alessia Campomori, Devis Collura, Emanuela Viglietta, Lorenzo Muccioli, Martina Soldà, Veronica Viola, Nicolò Locatelli, Francesca Simonetti, Barbara Mostacci, Roberta Coa, Antonio Valentino Saporito, Vincenzo Belcastro, Valeria Badioni, Maria Grazia Pascarella, Luciano Pellegrino, Angelina Laganà, Rosario Beccore, Orazio Pardeo, Francesco Luppino, Serena Raineri, Stefano Meletti, Niccolò Biagioli, Matteo Pugnaghi, Giada Giovannini, Simona Scolastico, Margherita Burani, Lisa Taruffi, Cecilia Zivelonghi, Umberto Aguglia, Vittoria Cianci, Roberta Cutellè, Angelo Pascarella, Laura Buttarelli, Roberto Matrullo, Davide Toraldo, Chiara Di Blasi, Valeria Sarro, Antonio Volzone, Massimo Di Giovanni, Stefano Avventura, Maria Francesca Tepedino, Andrea Latino, Antonella Morea, Nicola Pilolli, Giuseppe Pontrelli, Luigi Vetri, Giulia Fatati, Sabina Bartalini, Giulia Maccanti, Giulia Beneduce, Damiano Bruno, Giacomo Evangelista, Michelangelo Dasara, Clarissa Corniello, Stefano Consoli, Davide Liviello, Paolo Quintieri, Francesco Habetswallner, Rosaria Renna, Vincenzo Loreto, Edward Cesnik, Carla Marcialis, Martina Romozzi, Costanza Sottani, Matteo Antonucci, Alessio D'Elia, Laura Carmillo, Lavinia Vassallo, Eloise Lo Mauro, Salvatore Maria Lima, Federica Cerasa, Barbara Chiocchetti, Martina Calistri, Andrea Scalvini, Elisabetta Del Zotto, Alice Figura, Giovanni Messina, Marta Maria Tentorio, Paolo Costa, Chiara Silvestri, Elisabetta Rolla, Leandro Purin, Luca Colombo, Morgan Trevisan, Gabriele Mainini, Romano Giovanni Orofino, Matteo Impellizzeri, Maria Cristina Servalli, Paolo Paone, Sara Mazzoleni, Martina Fanella, Teresa Francavilla, Daniele Graziani, Pamela Rosettani, Sara Zagaglia, Luciana Mollo, Azzurra Biagiotti, Alessandro Alesi, Maria Teresa Di Claudio, Pierangela Riani, Fabio Iannaccone, Claudia Scarpitta, Maria Proietto, Angelo Battiato, Salvatore Dominici, Martina Guadagni, Daniela Marino, Rossella Papetti, Marzia Carlini, Lucia Farotti, Marinella Tomaselli, Stefania Pavan, Matteo Cegalin, Elisa Montalenti, Giovanni Battista Rossi, Edoardo Della Sala, Claudio Gojani, Camilla Bertolini, Edoardo Pronello, Francesca Lozza   +206 more
wiley   +1 more source

Do preclinical seizure models predict success or failure in anti‐seizure drug development? A retrospective analysis of 89 compounds with divergent clinical outcomes for epilepsy

Epilepsia, EarlyView.
Abstract Anti‐seizure medication (ASM) discovery remains a major challenge despite over 30 commercially available options. One persistent obstacle for any promising candidate compound to successfully move from preclinical study to clinical approval has been the ambiguity in preclinical model selection.
Wolfgang Löscher, Melissa Barker‐Haliski   +1 more
wiley   +1 more source

Status epilepticus: Updates on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley   +1 more source

Treatment Persistence of Lacosamide, Perampanel and Brivaracetam: An Extended Real-World Analysis from the COMPARE Italian Cohort

Epidemiology, Biostatistics and Public Health
Objectives Antiseizure medication (ASM) discontinuation is a frequent and clinically meaningful outcome in the treatment of epilepsy, often reflecting inadequate tolerability, limited effectiveness, or both[1, 2].
Gianfranco Di Gennaro, R. Roberti, C. Politi, E. Russo, COMPARE Study Group   +4 more
doaj   +1 more source

Intraoperative electrocorticography guiding surgical resection in epilepsia partialis continua secondary to cardiac myxoma embolism: A clinical vignette

Epileptic Disorders, EarlyView.
Olalla Urdanibia‐Centelles, Annette Sidaros, Per Jensen, Ioannis Tsiropoulos, Giulia Primicerio, Trine Jessen, Rune Rasmussen, Jon Foss‐Skiftesvik   +7 more
wiley   +1 more source

Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care

Epilepsia Open, EarlyView.
Abstract Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of the most severe epilepsies, characterized by seizure onset and neurodevelopmental delay in infancy or childhood, often with additional neurological and systemic comorbidities.
Alex M. Dudley, Peter Widdess‐Walsh, Christine Linehan, Danielle M. Andrade, Norman Delanty, Patrick B. Moloney   +5 more
wiley   +1 more source

The Effect of Co-Administration of Levetiracetam or Brivaracetam with Ethanol on the Associative Learning and Anxiety Level of Rats

Future Pharmacology
Background: Ethanol intake leads to cognitive deficits. Recent research demonstrated that a dysregulation of synaptic vesicle glycoprotein 2A (SV2A) expression seems to be linked to anxiety and memory disorders.
Ewa Zwierzyńska, Bogusława Pietrzak
doaj   +1 more source

From triggers to ictal events: A video case series of reflex seizures

Epileptic Disorders, EarlyView.
Laure Salmon, Nicolas Nguyen, Dang Khoa Nguyen, Olivier Aron   +3 more
wiley   +1 more source